Total oxidant status, total antioxidant capacity and ischemia modified albumin levels in children with celiac disease

Sayar E, Özdem S, Uzun G, İşlek A, Yılmaz A, Artan R. Total oxidant status, total antioxidant capacity and ischemia modified albumin levels in children with celiac disease. Turk J Pediatr 2015; 57: 498-503. In our study, we aimed to investigate ischemia modified albumin (IMA) as an oxidative stress marker, as well as other oxidant and antioxidant markers that have not been evaluated in children with celiac disease. A total of 37 pediatric patients who were diagnosed with celiac disease (CD) and 29 healthy children were enrolled in this prospective study. We evaluated the IMA, total oxidant status, total antioxidant capacity, sulfhydryl, and advanced oxidation protein products in all of the subjects. We also compared the levels at the time of the diagnosis, and following a gluten-free diet (GFD) in the children with CD. While the IMA and the other oxidant marker levels were significantly higher in the patient group compared to the control group, the antioxidant marker levels were found to be significantly lower in the patient group, compared to the control group. We also determined that the tissue transglutaminase IgA showed a highly positive correlation, and that the IMA showed a moderately positive correlation with the Marsh-Oberhuber histopathological stage. Additionally, the IMA and other oxidant marker levels were significantly lower, while the antioxidant marker levels were significantly higher after the GFD, compared to the pre-diet period. We detected that oxidative stress played a role in the pathogenesis of CD, and that this could be evaluated using oxidative stress markers, which would regress after the GFD. We also detected that IMA is a marker that shows a correlation with the histopathological stage, and may be used in the diagnosis.

___

1. Fasano A, Catassi C. Clinical practice. Celiac disease. N Engl J Med 2012; 367: 2419-2426.

2. Ferretti G, Bachetti T, Masciangelo S, Saturni L. Celiac disease, inflammation and oxidative damage. Nutrients 2012; 4: 243-257.

3. McCord. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312: 159-163.

4. Berenshtein E, Mayer B, Goldberg C, Kitrossky N, Chevion M. Patterns of mobilization of copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J Mol Cell Cardiol 1997; 29: 3025-3034.

5. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011; 49: 177-184.

6. Kaefer M, Piva SJ, De Carvalho JA, et al. Association between ischemia-modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010; 43: 450-454.

7. Duarte MM, Rocha JB, Moresco RN, et al.

Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009; 42: 666-671. 8. Cichota LC, Moresco RN, Duarte MM, da Silva JE.

Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 2008; 22: 1-5.

9. Piva SJ, Duarte MM, Da Cruz IB, et al. Ischemiamodified albumin as an oxidative stress biomarker in obesity. Clin Biochem 2011; 44: 345-347.

10. Awadallah SM, Atoum MF, Nimer NA, Saleh SA. Ischemia modified albumin: an oxidative stress marker in ?-thalassemia major. Clin Chim Acta 2012; 413: 907-910.

11. Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54: 136-160.

12. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000; 19: 311-315.

13. Bar-Or D, Lau E, Rao N. Reduction in the cobalt binding capacity of human albumin with myocardial ischemia. Ann Emerg Med 1999; 34: 56.

14. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-119.

15. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111.

16. Koster JF, Biemon P, Swaak AJ. Intracellular and extracellular sulphydryl levels in rheumatoid arthritis. Ann Rheum Dis 1986; 45: 44-46.

17. Witko-Sarsat V, Friedlander M, Capeille're-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.

18. Lionetti E, Catassi C. New clues in celiac disease epidemiology, pathogenesis, clinical manifestations, and treatment. Int Rev Immunol 2011; 30: 219-231.

19. Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol 2010; 7: 203-213.

20. Heyman M, Men ard S. Pathways of gliadin transport in celiac disease. Ann N Y Acad Sci 2009; 1165: 274- 278. 21. Zimmer KP, Fischer I, Mothes T, et al. Endocytotic segregation of gliadin peptide 31-49 in enterocytes. Gut 2010; 59: 300-310.

22. Giovannini C, Maiuri L, De Vincenzi M. Cytotoxic effect of prolamin-derived peptides on in vitro cultures of cell line CaCo-2: Implications for coeliac disease. Toxicol In Vitro 1995; 9: 251-255.

23. Dolfini E, Elli L, Dasdia T, et al. In vitro cytotoxic effect of bread with gliadin on the LoVo human adenocarcinoma cell line. Toxicol In Vitro 2002; 16: 331-337.

24. Lavö B, Knutson L, Lööf L, Hallgren R. Gliadin challenge-induced jejunal prostaglandin E2 secretion in celiac disease. Gastroenterology 1990; 99: 703-707.

25. Stojiljkovic V, Todorovic A, Pejic S, et al. Antioxidant status and lipid peroxidation in small intestinal mucosa of children with celiac disease. Clin Biochem 2009; 42: 1431-1437.

26. Stahlberg MR, Hietanen E, Maki M. Mucosal biotransformation rates in the small intestine of children. Gut 1988; 29: 1058-1063.

27. Daniels I, Cavill D, Murray IA, Long RG. Elevated expression of iNOS mRNA and protein in coeliac disease. Clin Chim Acta 2005; 356: 134-142.

28. Beckett CG, Dell'Olio D, Ellis HJ, Rosen-Bronson S, Ciclitira PJ. The detection and localization of inducible nitric oxide synthase production in the small intestine of patients with coeliac disease. Eur J Gastroenterol Hepatol 1998; 10: 641-647.

29. Ter Steege J, Buurman W, Arends JW, Forget P. Presence of inducible nitric oxide synthase, nitrotyrosine, CD68, and CD14 in the small intestine in celiac disease. Lab Invest 1997; 77: 29-36.

30. Murray IA, Daniels I, Coupland K, Smith JA, Long RG. Increased activity and expression of iNOS in human duodenal enterocytes from patients with celiac disease. Am J Physiol Gastrointest Liver Physiol 2002; 283: 319-326.

31. Högberg L, Webb C, Falth-Magnusson K, et al. Children with screening-detected coeliac disease show increased levels of nitric oxide products in urine. Acta Paediatr 2011; 100: 1023-1027.

32. Alessio MG, Tonutti E, Brusca I, et al. Correlation between IgA tissue transglutaminase antibody ratio and histological finding in celiac disease. J Pediatr Gastroenterol Nutr 2012; 55: 44-49.

33. Zanini B, Magni A, Caselani F, et al. High tissuetransglutaminase antibody level predicts small intestinal villous atrophy in adult patients at high risk of celiac disease. Dig Liver Dis 2012; 44: 280-285.

34. Ertekin V, Selimoğlu MA, Türkan Y, Akçay F. Serum nitric oxide levels in children with celiac disease. J Clin Gastroenterol 2005; 39: 782-785.

35. Szaflarsaka-Poplawska A, Siomek A, CzerwionkaSzaflarska M, et al. Oxidatively damaged DNA/oxidative stres in children with celiac disease. Cancer Epidemiol Biomarkers Prev 2010; 19: 1960-1965.
Turkish Journal of Pediatrics-Cover
  • ISSN: 0041-4301
  • Yayın Aralığı: Yılda 6 Sayı
  • Başlangıç: 1958
  • Yayıncı: Hacettepe Üniversitesi Çocuk Sağlığı Enstitüsü Müdürlüğü
Sayıdaki Diğer Makaleler

Development of a screening tool for children's growing pains: validation, reliability control and clinical evaluation

Maria VASİLOPOULOU, Anastasios SPATHİS, Nikos MYRİOKEFALİTAKİS, Foteni ZAFEROPOULOU, Ioanna PASPATİ, Maria TSOLİA

Total oxidant status, total antioxidant capacity and ischemia modified albumin levels in children with celiac disease

Ersin SAYAR, SEBAHAT ÖZDEM, Gülbahar UZUN, ALİ İŞLEK, Aygen YILMAZ, Reha ARTAN

Childhood epilepsy with occipital paroxysm: classification, atypical evolution and long-term prognosis in 35 patients

Ayşe AKSOY, VİLDAN GÖKNUR HALİLOĞLU, DİLEK YALNIZOĞLU, Güzide TURANLI

Prolonged pacifier usage in infancy does not cause eating behavior problem later

Elif Nursel ÖZMERT, Nurcan BULUR, Nazan KAYMAZ, Mustafa TEKİN, Şule YILDIRIM, Fatih Köksal BİNNETOĞLU, Mustafa KILIÇ, Naci TOPALOĞLU, Sibel CEVİZCİ

A case of hyperkinetic movement disorder associated with LGI1 antibodies

ÇİĞDEM SEVDA ERER ÖZBEK, Zuhal YAPICI, Erdem TÜZÜN, Murat GİRİŞ, Selcen DURAN, Özlem TAŞKAPILIOĞLU, Mehmet OKAN

Development of a screening tool for children's growing pains: validation, reliability control and clinical evaluation

Maria VASİLOPOULOU, Anastasios SPATHİS, Nikos MYRİOKEFALİTAKİS, Foteni ZAFEROPOULOU, Ioanna PASPATİ, Maria TSOLİA

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis

Aysel ÜNLÜSOY-AKSU, SİNAN SARI, Güldal YILMAZ, ÖDÜL EĞRİTAŞ GÜRKAN, Zeliha DEMİRTAŞ, Buket DALGIÇ

Clinical and neuroradiologic variability of Aicardi-Goutiéres syndrome: Two siblings with RNASEH2C mutation and a boy with TREX1 mutation

Hülya MARAŞ-GENÇ, Emek UYUR-YALÇIN, Bülent KARA

A rare but important adverse effect of tacrolimus in a heart transplant recipient: diabetic ketoacidosis

Selman KESİCİ, Benan BAYRAKÇI, İlker ERTUĞRUL, Zeynelabidin ÖZTÜRK, Leman AKCAN, E. Nazlı GÖNÇ

A rare hydrocephalus complication: cortical blindness

EMRE ÜNAL, RAHŞAN GÖÇMEN, AYŞE İLKSEN ÇOLPAK IŞIKAY, ÖZLEM TEKŞAM